![](/img/cover-not-exists.png)
Assessment of the Key Drivers of Cost-Effectiveness in the Economic Modelling of Canagliflozin (CANA) Versus Glimepiride (GLIM) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the UK Setting
Thompson, G., Willis, M., Johansen, P., Neslusan, C., Schroeder, M., Girod, I.Volume:
16
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2013.08.680
Date:
November, 2013
File:
PDF, 59 KB
english, 2013